Petros Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
PTPI$0.07-46.5%Stored close · as of May 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description | |
| 10.1# | | Executive Compensation Agreement, by and between Petros Pharmaceuticals, Inc. and Joshua Silverman, dated as of August 13, 2025 (incorporated by reference to 10.1 to the Company’s Quarterly Report on Form 10-Q filed on August 14, 2025). |
| 31.1* | | Rule 13a-14(a)/15d-14(a) Certification – Principal Executive Officer. |
| 31.2* | | Rule 13a-14(a)/15d-14(a) Certification – Principal Financial Officer. |
| 32.1** | | Section 1350 Certification – Principal Executive Officer. |
| 32.2** | | Section 1350 Certification – Principal Financial Officer. |
| 101 | | The following materials from Petros Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Changes in Stockholders’ Equity/Members’ Capital; (iv) Consolidated Statements of Cash Flows; and (v) Notes to the Consolidated Financial Statements. |
| 104 | | Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101. |
| * | Filed herewith. |
|---|
| ** | Furnished herewith. |
|---|
| # | Management contract or compensatory plan or arrangement. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.